Premium
Cardiovascular events in survivors of high‐dose chemotherapy for germ cell tumors
Author(s) -
Ishioka JunIchiro,
Fujii Yasuhisa,
Kageyama Yukio,
Fukuda Hiroshi,
Higashi Yotsuo,
Kihara Kazunori
Publication year - 2008
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2008.02066.x
Subject(s) - carboplatin , medicine , ifosfamide , etoposide , cisplatin , germ cell tumors , chemotherapy , testicular cancer , urology , oncology , cumulative dose , surgery
The objective was to investigate cardiovascular complications in long‐term survivors treated by high‐dose chemotherapy. We analyzed 13 previously successfully treated metastatic germ cell cancer patients. The patients ranged in age from 16 to 38 years (median: 27 years). Patients were treated by high‐dose ifosfamide, carboplatin and etoposide (ICE) or high‐dose etoposide, ifosfamide and cisplatin (VIP). In a minimal follow‐up of 48 months, the incidence of cardiovascular events and the accumulated doses of platinum were analyzed from the total amounts of cisplatin and/or carboplatin. The calculated accumulated doses of platinum ranged from 487 to 4302 mg (median: 2297 mg). Cardiovascular events were observed in two patients who received cumulative doses of more than 3000 mg of platinum. Survivors of high‐dose chemotherapy may have a risk of developing cardiovascular complications during the early phase of follow‐up. In particular, patients who have received carboplatin‐based high dose chemotherapy require careful observation.